Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals has applied to the ASX for quotation of 415,031,847 new fully paid ordinary shares, to be issued on 10 April 2026. The large volume of new securities, issued following a previously announced transaction, will significantly expand the company’s quoted share base and may affect liquidity, ownership structure and market valuation for existing and new investors.
The application under Appendix 2A formalises the listing of these securities on the ASX and reflects the latest step in executing capital-related plans previously flagged to the market. While specific use of proceeds or strategic rationale is not detailed in the filing, the scale of the issuance suggests a material capital or transaction event with potential implications for Botanix’s funding capacity and future growth initiatives.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an Australian-listed pharmaceutical company trading on the ASX under the code BOT. The company operates in the biotechnology and drug development industry, focusing on pharmaceutical products and therapies underpinned by clinical research for healthcare markets.
Average Trading Volume: 14,000,286
Technical Sentiment Signal: Sell
Current Market Cap: A$88.72M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.